Please login to the form below

Not currently logged in

China approves Pfizer's Wyeth acquisition

Pfizer has announced it has received approval for its pending acquisition of Wyeth from China's Ministry of Commerce

China's Ministry of Commerce has given Pfizer approval for its pending takeover of Wyeth, which includes a commitment from Pfizer to sell certain animal health assets in the country.

Jeff Kindler, chairman and CEO at Pfizer said: "We are pleased to have achieved another significant milestone with the Ministry's approval of the pending transaction."

Wyeth shareholders approved the merger in July 2009 following an announcement that the deal had been cleared by the European Commission under the European Union Merger Regulation authorisation process.

Approvals from regulators and governments on several continents were required before the deal agreed in January 2009 could go ahead due to the size of the businesses involved.

The completion of the acquisition is dependent on regulatory approval from Australia, Canada and the US, which are expected shortly. Pfizer hopes to close the transaction in the early part of Q4 2009.

29th September 2009


Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...